Scientists at McMaster University who have developed an inhaled form of COVID vaccine have confirmed it can provide broad, long-lasting protection against the original strain of SARS-CoV-2 and variants of concern.
The research, recently published in the journal Cell, reveals the immune mechanisms and significant benefits of vaccines being delivered directly into the respiratory tract, rather than by traditional injection. The laboratory and the researchers are part of McMaster’s Global Nexus for Pandemics and Biological Threats.
Because inhaled vaccines target the lungs and upper airways where respiratory viruses first enter the body, they are far more effective at inducing a protective immune response, the researchers report.
The reported preclinical study, which was conducted on animal models, has provided the critical proof of concept to enable a Phase 1 clinical trial that is currently under way to evaluate inhaled aerosol vaccines in healthy adults who had already received two doses of a COVID mRNA vaccine.
The tested COVID vaccine strategy was built upon a robust tuberculosis vaccine research program established by Zhou Xing, a co-lead author of the new study and a professor at the McMaster Immunology Research Centre and Department of Medicine.
“What we’ve discovered from many years’ research is that the vaccine delivered into the lung induces all-around protective respiratory mucosal immunity, a property that the injected vaccine is lacking,” Xing says.
Currently authorized COVID vaccines are all injected.
“We wanted, first and foremost, to design a vaccine that would work well against any variant,” explains the study’s co-lead author Matthew Miller, an associate professor at McMaster’s Michael G. DeGroote Institute for Infectious Disease Research.
The McMaster COVID vaccine represents one of only a handful developed in Canada. The urgent work is a critical mission of Canada’s Global Nexus for Pandemics and Biological Threats, which is based at McMaster.
Researchers compared two types of adenovirus platforms for the vaccine. The viruses serve as vectors that can deliver vaccine directly to the lungs without causing illness themselves.
“We can remain ahead of the virus with our vaccine strategy,” says Miller. “Current vaccines are limited because they will need to be updated and will always be chasing the virus.”
Both types of the new McMaster vaccine are effective against highly transmissible variants because they are designed to target three parts of the virus, including two that are highly conserved among coronaviruses and do not mutate as quickly as spike. All COVID vaccines currently approved in Canada target only the spike protein, which has shown a remarkable ability to mutate.
“This vaccine might also provide pre-emptive protection against a future pandemic, and that’s really important because as we’ve seen during this pandemic – and as we saw in 2009 with the swine flu – even when we are able to rapidly make a vaccine for a pandemic virus, it’s already way too late. Millions of people died, even though we were able to make a vaccine in record time,” says Miller.
“We have revealed in our report that besides neutralizing antibodies and T cell immunity, the vaccine delivered into the lungs stimulates a unique form of immunity known as trained innate immunity, which is able to provide very broad protection against many lung pathogens besides SARS-CoV-2,” Xing adds.
In addition to being needle and pain-free, an inhaled vaccine is so efficient at targeting the lungs and upper airways that it can achieve maximum protection with a small fraction of the dose of current vaccines – possibly as little as 1 per cent – meaning a single batch of vaccine could go 100 times farther, the researchers say.
“This pandemic has shown us that vaccine supply can be a huge challenge. Demonstrating that this alternative delivery method can significantly extend vaccine supply could be a game changer, particularly in a pandemic setting,” says Brian Lichty, an associate professor in the Department of Medicine who co-led the preclinical study along with Miller, Xing and the senior trainees Sam Afkhami and Michael D’Agostino, who are the joint first authors of the study.
More from: McMaster University
The Latest on: Inhaled Covid vaccine
- US risks falling behind foreign competitors on next generation vaccines. Congress must act nowon December 6, 2022 at 4:35 pm
As the United States heads into its third pandemic winter, White House COVID Coordinator Ashish Jha says regarding tools: “the medicine cabinet has actually shrunk.” While the rapid ...
- COVID Tracker: Nearly 700 new cases reported in San Antonio Tuesdayon December 6, 2022 at 3:24 pm
Bexar County on Tuesday recorded 697 new COVID-19 cases, the biggest single-day tally in more than three months and a figure that puts into sharp relief a trend the San Antonio area has been ...
- China Approves Second Nasal Spray Covid-19 Vaccineon December 6, 2022 at 1:21 pm
China granted emergency approval for a second nasal spray Covid-19 vaccine as the country battles a surge in cases while easing its stringent “zero-Covid” disease-control policy. A product developed ...
- Health officials make urgent push for flu and COVID shots as hospitals feel the strainon December 5, 2022 at 2:42 pm
Health officials are making another urgent push to encourage flu and COVID vaccinations, as multiple respiratory viruses swirl around the country.
- Fauci says China’s vaccines are ‘not at the level’ of Western ones, hindering Beijing’s ability to control COVID without ‘draconian’ lockdownson December 2, 2022 at 1:26 am
But a bigger problem for Beijing may be the number of elderly Chinese who have yet to get their booster shots.
- Column: COVID boosted anti-vaccine propaganda. Now measles and other childhood diseases are on the marchon November 30, 2022 at 12:37 pm
The anti-vaccination movement grew stronger during the COVID pandemic. The result is a surge in measles and other preventable diseases.
- China needs at least a year to end zero-COVID policy, experts sayon November 30, 2022 at 6:39 am
A renewed push by China to vaccinate elderly people has sparked hopes for an end to its zero-COVID policy, but it may take a year to get there.
- China to ramp up COVID vaccinations for its elderlyon November 29, 2022 at 3:56 pm
China will speed up COVID-19 vaccinations for elderly people, health officials said on Tuesday, aiming to overcome a key stumbling block in efforts to ease unpopular "zero-COVID" curbs.
- BiondVax reports successful results in preclinical in vivo study of its innovative inhaled COVID-19 NanoAb therapyon November 29, 2022 at 5:36 am
BiondVax’s nanosized antibodies (NanoAbs) are being formulated as a convenient self-administered, at-home, inhaled COVID-19 therapy The COVID-19 therapy is BiondVax’s first in a new pipeline of ...
- China’s zero-COVID strategy makes no sense and its homegrown vaccines are not ‘particularly effective,’ says Faucion November 29, 2022 at 3:49 am
Widespread protests across China over the government's zero-COVID policy dominated headlines on the pandemic on Monday.
via Bing News
The Latest on: Inhaled Covid vaccine
[google_news title=”” keyword=”inhaled Covid vaccine” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News